Claims for Patent: 7,820,142
✉ Email this page to a colleague
Summary for Patent: 7,820,142
Title: | Immunogenic glycopeptides, screening, preparation and uses |
Abstract: | The invention relates to immunogenic glycopeptides derived from pathogenic microorganisms, which can be used for immunization and diagnosing infections dye to such pathogenic microorganisms and also to method for the selection and preparation thereof. |
Inventor(s): | Marchal; Gilles (Ivry-sur-Seine, FR), Romain; Felix (Fontenay-les-Briis, FR), Pescher; Pascale (Issy les Moulineaux, FR), Baleux; Francoise (Paris, FR), Scott-Algara; Daniel (Champigny-sur-Marne, FR), Mulard; Laurence (Le Kremlin-Bic tre, FR) |
Assignee: | Institut Pasteur (Paris, FR) |
Application Number: | 10/953,095 |
Patent Claims: | 1. A method for diagnosing tuberculosis in a patient, the method comprising the step of: detecting a M. tuberculosis Apa protein-specific CD4+ T lymphocyte response in
vivo or in vitro in said patient, wherein said CD4+ T lymphocyte response is directed to a glycopeptide consisting of SEQ ID NO:1 which extends from position 1 to 39 of the M. tuberculosis Apa protein sequence, and in which at least one threonine at
position 10, 18 and 27 of SEQ ID NO:1 is bonded to a dimannose or trimannose via a glycosidic bond, and wherein said detected CD4+ T lymphocyte response is indicative of tuberculosis in said patient and differentiates tuberculosis from an immunization
with BCG (Bacillus Calmette-Guerin).
2. The method according to claim 1, comprising the steps of: administering said glycopeptide to the patient, and detecting said CD4+ T lymphocyte response directed to said glycopeptide. 3. The method according to claim 1, comprising the steps of: bringing a biological sample from said patient into contact with said glycopeptide, and detecting said CD4+ T lymphocyte response directed to said glycopeptide. 4. The method according to claim 1, wherein said detection is carried out by a lymphocyte proliferation assay. 5. The method according to claim 1, wherein said detection is carried out by a cytokine assay. 6. The method according to claim 2, wherein said detection is carried out by a delayed-type hypersensitivity assay. 7. The method according to claim 3, wherein said biological sample consists of peripheral blood mononuclear cells. 8. The method according to claim 1, wherein said dimannose or trimannose comprises an .alpha.-(1,2) glycosidic bond. |
Details for Patent 7,820,142
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2040-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.